Rticc
Seleccione idioma:  
Buscar:
RTICC 2013
Programas RTICC
Agenda
Seguimiento cientifico
 
INTRODUCTION

The RTIC call includes a program entitled “otros tumores y pediátricos”. In the present RTIC proposal this program was designed to cover three different areas of cancer research which pose a significant amount of mortality and morbidity in special demographic groups (children, women). These areas of cancer research are usually underfinanced and out of the main focus of the pharma industry. This program includes research on tumors of the nervous system, pediatric solid tumors, and gynaecological tumors, with emphasis in endometrial carcinoma. + more...

OBJECTIVES

INNOVATION

TECHNOLOGY TRANSFER

FUNCTIONAL STRUCTURE OF THE PROGRAMME

SYNERGIES

CRITICAL MASS

MANAGEMENT OF THE PROGRAM

ADDED VALUE OF THE RESEARCH GROUPS

LETTERS OF SUPPORT

IMPACT AND TRANSFER

SCHEME OF EVALUATION OF THE PROGRAMME

Introducción
Coordinador
Grupos
Work Packages
Publicaciones
Proyectos
Ensayos clínicos
Otros resultados
Agenda
Enlaces
Intranet
Noticias
03/03/2017 | Otras reuniones
13/11/2016 | Otras reuniones
Publicaciones
RD12/0036/0012
Unveiling changes in the landscape of patient populations in cancer early drug development.
Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J
Oncotarget  2017.  8.  14158-14172.  PMID: 27835915. 

RD12/0036/0012
The expanding role of immunotherapy.
Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J
Cancer Treat Rev  2017.  74-86.  PMID: 28231560. 

RD12/0036/0012
The consensus molecular subtypes of colorectal cancer.
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S
Nat Med  2015.  11.  1350-6.  PMID: 26457759. 

RD12/0036/0012
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J
Ann Oncol  2016.  11.  2082-2090.  PMID: 27573561. 

RD12/0036/0012
Single-cell transcriptome conservation in cryopreserved cells and tissues.
Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H
Genome Biol  2017.  1.  45.  PMID: 28249587. 

RD12/0036/0012
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients.
Sclafani F, Chau I, Cunningham D, Lampis A, Hahne JC, Ghidini M, Lote H, Zito D, Tabernero J, Glimelius B, Cervantes A, Begum R, De Castro DG, Wilson SH, Peckitt C, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Braconi C, Valeri N
Carcinogenesis  2016.  9.  852-7.  PMID: 27381831. 

RD12/0036/0012
SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
Vera R, Dotor E, Feliu J, González E, Laquente B, Macarulla T, Martínez E, Maurel J, Salgado M, Manzano JL
Clin Transl Oncol  2016.  12.  1172-1178.  PMID: 27896637. 

RD12/0036/0012
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D
Br J Cancer  2016.  9.  e13.  PMID: 27657342. 

RD12/0036/0012
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D
Br J Cancer  2016.  2.  188-94.  PMID: 27351217. 

RD12/0036/0012
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O
Target Oncol  2017.  1.  19-35.  PMID: 27844272. 

ISCII
ISCII
 
Ministerio de Economia y Competitividad
Descargar
Red Temática Investigación Cooperativa Sanitaria
Rticc 2012
Logotipos
 
ISCII
Red Temática Investigación Cooperativa en Cáncer (RTICC)
Centro de Investigación Cáncer - Campus Miguel de Unamuno - 37007 - Salamanca
(+34) 923294803 - sec.rticc[arroba]usal.es
|
|
|
|
 
Sobre la RTICC Programas RTICC Ofertas de empleo y Agenda Seguimiento científico
Red Temática de Investigación Cooperativa en Cáncer · © Copyright 2013 · sec.rticc[arrroba]usal.es · diseño web: detrazos
RSS